{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreif5hfxzk6au7bkxhthf3re52deymbvy2c2dusnbori565t3cpttxm",
    "uri": "at://did:plc:3ueatpf6zh5nibd6nd3pao4o/app.bsky.feed.post/3mfdgrxpdqme2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreif6zzv4zgtjl7sjq2kgocsgbn7ankuuglghq5a34pgy7om2j467du"
    },
    "mimeType": "image/jpeg",
    "size": 164332
  },
  "path": "/hims-hers-eucalyptus-acquisition-glp-1-pills-fda/",
  "publishedAt": "2026-02-20T23:04:13.000Z",
  "site": "https://athletechnews.com",
  "tags": [
    "Wellness",
    "FDA",
    "GLP-1s",
    "Healthcare",
    "Hims & Hers",
    "Novo Nordisk",
    "Hims & Hers Goes Global While GLP-1 Drama Plays Out at Home",
    "Athletech News"
  ],
  "textContent": "Hims & Hers is planting its flag in new overseas markets; on U.S. soil, it's navigating a GLP-1s fight against Big Pharma's branded blockbusters.\n\nThe post Hims & Hers Goes Global While GLP-1 Drama Plays Out at Home appeared first on Athletech News.",
  "title": "Hims & Hers Goes Global While GLP-1 Drama Plays Out at Home"
}